Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
成長中
同社は成長フェーズにあり、最新の年間収益はUSD 59.34Mに達しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 94.32です。
適正水準
同社の最新のPEは-3.04で、過去3年間の水準と比較して適正圏にあります。
機関投資家の売り越し
最新の機関投資家の保有株数は75.27M株で、前四半期比で8.29%減少しています。
バンガードが保有
スター投資家バンガードは本銘柄を4.59M株保有しています。
市場活動が活発
同社への投資家の関心が高まっており、20日間の売買回転率は0.67です。